This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.
OVERVIEW OF ACTIVITY
Ovarian cancer is the fifth leading cause of mortality from cancer among women, and survival rates remain low as most patients present with advanced manifestations of the disease. This poor prognosis is attributable to the inadequate effect of chemotherapy as primary treatment after optimal debulking surgery because an estimated 70% of patients will experience relapse despite receiving standard therapy. To improve this dynamic, different strategies, such as neoadjuvant chemotherapy and intravenous versus intraperitoneal chemotherapy, have been evaluated and subsequently introduced into the treatment milieu. In reality, however, these have done little to modify the natural course of the disease. Angiogenesis inhibition is another rational strategy that has been assessed, most notably with bevacizumab. Angiogenesis is an important process contributing to the progression of ovarian cancer, and randomized trials support the recent FDA approval of bevacizumab in combination with carboplatin and paclitaxel followed by single-agent bevacizumab for patients with advanced disease after initial surgical resection.
Consensus-based guidelines such as those published by NCCN (National Comprehensive Cancer Network), ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) aim to support oncologists and other cancer clinicians in making rational treatment recommendations. However, in situations where multiple “acceptable” therapeutic options exist such guidelines may not be particularly helpful at the time of decision-making. Because these resources simply enumerate all diagnostic or treatment strategies supported by diverse levels of evidence rather than providing perspectives on the benefits and risks of one strategy over another, they often leave the clinician to discern whether an optimal clinical approach exists and what it would be. To bridge the gap between research and patient care, this CME program features in-depth discussions with Dr Bradley J Monk and Prof Jonathan A Ledermann to review key research information, including clinical trial designs, published data sets and ongoing and planned study concepts, and also presents review and analysis of the results from a comprehensive survey of 24 medical and gynecologic oncology experts focused on the management of newly diagnosed ovarian cancer.
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 2.25 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OCInvestigators19/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/OCInvestigators19/Video.
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OCInvestigators19/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OCInvestigators19.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Professor Jonathan A Ledermann
Professor of Medical Oncology
University College London Cancer Institute
Director, Cancer Research UK and UCL Cancer Trials Centre
London, United Kingdom
Advisory Committee: Artios Pharma, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Cristal Therapeutics, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme Corp; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology.
Bradley J Monk, MD
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine
St Joseph’s Hospital
US Oncology Research Network – Gynecologic Program
Consulting Agreements: AbbVie Inc, Advaxis Inc, Agenus Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Clovis Oncology, Conjupro Biotherapeutics Inc, Genentech, Genmab, Gradalis Inc, ImmunoGen Inc, Immunomedics, Incyte Corporation, Janssen Biotech Inc, Mateon Therapeutics, Merck, Myriad Genetic Laboratories Inc, Perthera Inc, Pfizer Inc, Precision Therapeutics Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Samumed, Takeda Oncology, Tesaro, VBL Therapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Janssen Biotech Inc, Roche Laboratories Inc, Tesaro.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from Genentech.
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Release date: June 2019
Expiration date: June 2020
After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.